Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)–Like Pigmentation in a Metastatic Breast Cancer Patient

Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved in combination with endocrine therapy for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative advanced or metastatic breast cancer. The main dermatological adverse events asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariano, Maria, Donati, Pietro, Cameli, Norma, Pigliacelli, Flavia, Morrone, Aldo, Cristaudo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920864/
https://www.ncbi.nlm.nih.gov/pubmed/33634626
http://dx.doi.org/10.4048/jbc.2021.24.e1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920864/
https://www.ncbi.nlm.nih.gov/pubmed/33634626
http://dx.doi.org/10.4048/jbc.2021.24.e1

Ejemplares similares